Strategic agreement brings Inocras’ cancer whole genome data and cancer intelligence platform into AimedBio’s ADC clinical trials, supported by a strategic equity investment
Inocras Inc., a U.S.-based precision medicine company, announced a strategic partnership with AimedBio, a South Korean biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer. As part of the agreement, AimedBio has made a strategic equity investment in Inocras, and the two companies have signed a joint research agreement to integrate Inocras’s whole genome sequencing (WGS) capabilities into AimedBio’s clinical programs.
Under the agreement, AimedBio will apply Inocras’ whole genome sequencing (WGS), cancer intelligence platform, and multi-omics analysis across its ADC clinical trials to support biomarker identification, patient selection, and novel cancer target discovery. By leveraging comprehensive cancer whole genome data, the collaboration aims to accelerate clinical development while uncovering new opportunities for precision drug discovery. The two companies also plan to explore joint commercial opportunities, connecting AimedBio’s precision drug screening business with Inocras’s diagnostic platform across global markets.
Also Read: Inocras and KAIST Launch DNAChunker for DNA Language Models
“This partnership reflects what we’ve believed from the start, that cancer whole genome data has a role beyond diagnosing cancer. It can directly shape how new treatments are developed and identify which patients are most likely to benefit,” said Jehee Suh, CEO of Inocras. “Bringing our cancer intelligence platform into active clinical trials with AimedBio is an important step toward accelerating precision oncology and drug discovery, and we’re happy to welcome them as a strategic partner.”
Nam-Gu Her, CEO of AimedBio, said: “As ADC development grows more competitive, identifying which patients are most likely to respond to a given therapy becomes a decisive advantage. Inocras‘s genomic capabilities will support biomarker research, patient stratification, and the discovery of next-generation cancer targets, further strengthening AimedBio’s precision oncology platform.”
Source: Businesswire